A77 1726 manufacturers and suppliers in india

A77 1726

Properties

Melting point:: 229-232°C

Boiling point:: 410.8±45.0 °C(Predicted)

Density: 1.424±0.06 g/cm3(Predicted)

storage temp.: -20°C

solubility: DMSO: soluble5mg/mL, clear (warmed)

pka: 5.20±0.50(Predicted)

form: powder

color: white to beige

λmax: 203nm(MeOH)(lit.)

Merck: 14,9165

Stability:: Hygroscopic

InChIKey: UTNUDOFZCWSZMS-YFHOEESVSA-N

Safety Information

Symbol(GHS): GHS07

Signal word: Warning

Hazard statements: H225-H302+H312+H332-H319

Precautionary statements: P210-P280-P301+P312-P303+P361+P353-P304+P340+P312-P305+P351+P338

Hazard Codes: Xn

Risk Statements: 22

WGK Germany: 3

HS Code: 2926.90.4801

Use

A-771726 is the active metabolite of leflunomide, a prodrug approved by the FDA for treatment of rheumatoid arthritis. A-771726 reversibly inhibits dihydroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines. It prevents activated lymphocytes from accumulating sufficient pyrimidines to support DNA synthesis (IC50s = 0.09, 3.5, and 12.5 μM for rat, mouse, and human, respectively). At higher doses, A-771726 inhibits tyrosine kinases responsible for early T cell and B cell signaling in the G0/G1 phase of the cell cycle. A-771726 has also been shown to inhibit the production of prostaglandin E2 in synoviocytes activated by TNF-α and IL-1α (IC50s = 7 and 3 μM, respectively) as well as inhibit MMP-1 and IL-6 production at concentrations >10 μM.[Cayman Chemical]